Last reviewed: July 8, 2026
Last updated: July 8, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Mounjaro (tirzepatide) and Wegovy (semaglutide) are both GLP-1 receptor agonists approved for weight loss, but they work through different pathways and deliver different results for different people. Many patients wonder if switching between them makes sense, and the answer depends on your individual response, side effects, and treatment goals. PlexusDx helps you explore both medications with transparent pricing and personalized genetic insights.
How Tirzepatide and Semaglutide Work Differently
Mounjaro contains tirzepatide, a dual GIP and GLP-1 receptor agonist that activates two distinct hormone pathways in your body. Wegovy contains semaglutide, which targets only the GLP-1 receptor. This dual-pathway approach in tirzepatide may produce greater weight loss in some patients—clinical trials showed tirzepatide users lost up to 22% of body weight compared to 17% with semaglutide over 68 weeks.
The PlexusDx Precision Peptide Genetic Test analyzes GLP1R, and GIPR — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.
Reasons Patients Switch from Tirzepatide to Semaglutide
Switching from Mounjaro to Wegovy typically happens when patients experience side effects they can't tolerate, hit a weight-loss plateau, or find that the dual-pathway stimulation causes gastrointestinal distress that interferes with daily life. Some people develop nausea or appetite suppression so pronounced that maintaining adequate nutrition becomes difficult. Others experience constipation or pancreatitis-like symptoms that resolve when switching to a single-pathway GLP-1 medication.
Cost considerations also drive switches. While PlexusDx compounded tirzepatide injection starts at $289/mo (or $249/mo on the 6-month plan) flat, switching to compounded semaglutide injection at $189/mo (or $149/mo on the 6-month plan) can reduce your monthly investment while you reassess your tolerance. A lower-dose semaglutide protocol may maintain your weight-loss progress while minimizing side effects, making it a practical middle ground before abandoning GLP-1 therapy altogether.
Reasons to Stay with Tirzepatide or Switch to It
If you've experienced modest weight loss on semaglutide alone, switching to tirzepatide offers the potential for greater fat reduction due to the added GIP pathway activation. Tirzepatide users in clinical trials showed faster initial weight loss and more sustained results over 12–18 months compared to semaglutide users. If your primary goal is maximum weight loss and you tolerate the medication well, tirzepatide remains the stronger pharmacologic choice based on available evidence.
Genetic factors also influence this decision. If your Precision Peptide Genetic Test reveals favorable variants in both GLP1R (rs6923761) and GIPR (rs1800437) pathways, tirzepatide targets both, maximizing your genetic predisposition for response. PlexusDx compounded tirzepatide injection remains flat-priced at $289/mo (or $249/mo on the 6-month plan) regardless of dose increases, so you won't face price escalation if your provider titrates your therapy upward—keeping your financial commitment stable while optimizing your clinical outcome.
How to Safely Switch Between GLP-1 Medications
Switching from Mounjaro to Wegovy or vice versa should always be done under medical supervision. Most providers recommend a washout period of 3–7 days between stopping one medication and starting the other to reduce overlap and allow your system to stabilize. Starting the new medication at a lower dose—typically the initial titration level—prevents dose-stacking effects that could amplify nausea or other side effects.
The PlexusDx Precision Peptide Genetic Test analyzes GLP1R, GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to Mounjaro or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.
Cost Comparison: Mounjaro vs. Compounded Alternatives
Brand-name Mounjaro prices vary widely by insurance coverage and pharmacy, often ranging from $800–$1,200 per month without insurance negotiation. PlexusDx compounded tirzepatide injection costs $289/month flat—a 70–80% reduction—and that price remains locked regardless of dose increases. Your dose may go up as your provider titrates your therapy, but your price won't, eliminating surprise cost escalations that plague patients on brand medications.
If you switch to semaglutide, PlexusDx compounded injection starts at $189/month, offering even greater savings while maintaining the same efficacy window for many patients. Both medications remain available through licensed 503A compounding pharmacies with no membership fees, no insurance required, and HSA/FSA eligibility. Adding PlexusDx Precision Peptide Genetic Test ($99 after your first treatment month) personalizes the switch decision by mapping your genetic response patterns across 150+ peptide-pathway insights.
Should You Get Genetic Testing Before Switching?
PlexusDx Precision Peptide Genetic Test is a peptide-pathway genetic assessment—not a traditional pharmacogenomic test—that maps how your DNA influences response to GLP-1, GIP, FTO, MC4R, and 10 additional regulatory pathways. Testing before or early in your GLP-1 journey reduces switching frequency by predicting which compound aligns with your genetic architecture. Patients with strong GLP1R variants but weaker GIPR expression may experience better outcomes on semaglutide alone, while those with robust dual-pathway genetics often thrive on tirzepatide.
The test costs $99 and activates after your first month of treatment, giving your provider data-driven context for dose adjustments and medication selection. Instead of trial-and-error switching, genetic insights allow precision matching of medication to biology, reducing side effects, accelerating weight loss, and increasing long-term treatment adherence. For patients considering a switch, genetic test results often clarify whether the problem is the wrong compound or simply a suboptimal dose of the current medication.
How Your Genetics Relate to GLP-1 Pathways
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $289/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Can I switch from Mounjaro to Wegovy without waiting?
You can switch, but a 3–7 day washout period is recommended to prevent dose overlap and reduce side effects. PlexusDx works with your provider to coordinate the transition safely across all 50 states without insurance barriers or delays.
Will I lose more weight on tirzepatide than semaglutide?
No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GLP1R, GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.
How much can I save by switching to PlexusDx compounded GLP-1 medications?
PlexusDx compounded tirzepatide injection starts at $289/mo (or $249/mo on the 6-month plan) and semaglutide at $189/month—typically 70–80% less than brand prices. Your price remains flat regardless of dose increases, and both are HSA/FSA eligible with no membership fees or insurance required.
What if I experience side effects on both tirzepatide and semaglutide?
Side effects often improve with slower dose titration, better hydration, and dietary adjustments. If both compounds cause intolerable symptoms, PlexusDx offers microdose GLP-1 Protocol at $129/month—a gentler entry point using lower initial doses. Your provider can also explore whether genetic variants in FTO or MC4R suggest alternative approaches.
How does PlexusDx Precision Peptide Genetic Test help me choose between Mounjaro and Wegovy?
No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GLP1R (rs6923761), and GIPR (rs1800437)) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.
Related Reading
Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Understanding the Side Effects of Using Ozempic
Is Zepbound FDA Approved for Sleep Apnea? Exploring Its Role in Treatment